Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | Ibrutinib vs temsirolimus in relapsed/refractory mantle cell lymphoma

Simon Rule • 4 Dec 2015
ASH 2015
Mantle Cell Lymphoma Ibrutinib Temsirolimus

Simon Rule, MD from Derriford Hospital, Plymouth, UK provides an overview of the RAY (MCL3001) study of ibrutinib vs temsirolimus in relapsed/refractory mantle cell lymphoma, presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. The primary endpoint was progression-free survival (PFS), which was 14.8 months for the ibrutinib arm and 6.6 months for the temsirolimus arm.

More from Simon Rule

Real-world results in the UK for ibrutinib at first relapsed for MCL
0:48
Real-world results in the UK for ibrutinib at first relapsed for MCL
Simon Rule • 7 Dec 2019
OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL
1:30
OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL
Simon Rule • 7 Dec 2019
Impressive results for R-BAC post BTKi in R/R MCL
1:28
Impressive results for R-BAC post BTKi in R/R MCL
Simon Rule • 7 Dec 2019
Long-term ibrutinib outcomes vs. prior regimens: pooled analysis in R/R MCL
1:35
Long-term ibrutinib outcomes vs. prior regimens: pooled analysis in R/R MCL
Simon Rule • 6 Dec 2019

Related Videos

Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
1:00
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
Yucai Wang • 10 Sep 2026
Lessons from the US: treatment access and patient-guided treatment selection in MCL
0:51
Lessons from the US: treatment access and patient-guided treatment selection in MCL
Elise Chong • 10 Sep 2026
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
1:23
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
Yucai Wang • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals